Harmony Biosciences Stock (NASDAQ:HRMY)
Previous Close
$33.89
52W Range
$28.14 - $41.61
50D Avg
$34.23
200D Avg
$33.07
Market Cap
$1.96B
Avg Vol (3M)
$750.73K
Beta
0.77
Div Yield
-
HRMY Company Profile
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
HRMY Performance
Peer Comparison
| Ticker | Company |
|---|---|
| RVMD | Revolution Medicines, Inc. |
| TVTX | Travere Therapeutics, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| REPL | Replimune Group, Inc. |
| FENC | Fennec Pharmaceuticals Inc. |
| JANX | Janux Therapeutics, Inc. |
| NUVL | Nuvalent, Inc. |
| KRON | Kronos Bio, Inc. |
| INZY | Inozyme Pharma, Inc. |
| GOSS | Gossamer Bio, Inc. |
| IDYA | IDEAYA Biosciences, Inc. |
| KROS | Keros Therapeutics, Inc. |
| VRDN | Viridian Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| VTYX | Ventyx Biosciences, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| GPCR | Structure Therapeutics Inc. |
| PTGX | Protagonist Therapeutics, Inc. |
| NVCT | Nuvectis Pharma, Inc. |
| VRNA | Verona Pharma plc |
| LYRA | Lyra Therapeutics, Inc. |